Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 7/20 | 0.83 |
| ▸ | DRD3 | P35462 | 5/20 | 0.83 |
| ▸ | USP2 | O75604 | 3/20 | 0.83 |
| ▸ | HRH2 | P25021 | 2/20 | 0.83 |
| ▸ | HTR2A | P28223 | 2/20 | 0.83 |
| ▸ | HTR2B | P41595 | 2/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.83 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.83 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.83 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.83 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.83 |
| ▸ | TEK | Q02763 | 1/20 | 0.83 |
| ▸ | DRD2 | P14416 | 4/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.71 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.71 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.71 |
| ▸ | DRD4 | P21917 | 1/20 | 0.71 |
| ▸ | HTR7 | P34969 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3847601 | 1.00 | HRH1 (0.83) | HRH1DRD3USP2HRH2HTR2A | |
| SCHEMBL3847012 | 1.00 | HRH1 (0.83) | HRH1DRD3USP2HRH2HTR2A | |
| SCHEMBL2058384 | 0.98 | HRH1 (0.80) | HRH1DRD3USP2HRH2HTR2A | |
| Hydrochloric Acid SCHEMBL10930111 | 0.97 | HRH1 (0.80) | HRH1DRD3USP2HRH2HTR2A | |
| SCHEMBL4665859 | 0.93 | HRH1 (0.70) | HRH1DRD3USP2HRH2HTR2A | |
| Cetirizine SCHEMBL14432665 | 0.91 | HRH1 (0.88) | HRH1DRD3USP2HRH2HTR2A | |
| Levocetirizine SCHEMBL4914 | 0.91 | DRD3 (1.00) | HRH1DRD3USP2HRH2HTR2A | |
| Cetirizine SCHEMBL2455487 | 0.91 | DRD3 (1.00) | HRH1DRD3USP2HRH2HTR2A | |
| Cetirizine SCHEMBL13724610 | 0.91 | DRD3 (1.00) | HRH1DRD3USP2HRH2HTR2A | |
| Levocetirizine SCHEMBL5935097 | 0.91 | DRD3 (1.00) | HRH1DRD3USP2HRH2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4763954-B2 | — | — | 2011-08-31 | — | — | JP | claimed |
| US-7619085-B2 | Pyroglutamate salts and their use in the optical resolution of intermediates for the synthesis of dextrocetirizine and levocetirizine | UCB PHARMA, S.A. (BE) | 2009-11-17 | — | — | US | claimed |
| EP-1858866-B1 | PYROGLUTAMATE SALTS AND THEIR USE IN THE OPTICAL RESOLUTION OF INTERMEDIATES FOR THE SYNTHESIS OF DEXTROCETIRIZINE AND LEVOCETIRIZINE | UCB FARCHIM SA (CH) | 2009-06-10 | — | — | EP | claimed |
| US-20080269489-A1 | Pyroglutamate Salts and Their Use in the Optical Resolution of Intermediates for the Synthesis of Dextrocetirizine and Levocetirizine | UCB PHARMA, S.A. (BE) | 2008-10-30 | — | — | US | claimed |
| EP-1858866-A1 | PYROGLUTAMATE SALTS AND THEIR USE IN THE OPTICAL RESOLUTION OF INTERMEDIATES FOR THE SYNTHESIS OF DEXTROCETIRIZINE AND LEVOCETIRIZINE | UCB FARCHIM, S.A. (CH) | 2007-11-28 | — | — | EP | claimed |
| US-7199241-B1 | Process for preparing (S) and (R)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide | UCB, S.A. (BE) | 2007-04-03 | — | — | US | claimed |
| US-20060252934-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl]piperazine | COSSEMENT ERIC | 2006-11-09 | — | — | US | claimed |
| WO-2006094648-A1 | PYROGLUTAMATE SALTS AND THEIR USE IN THE OPTICAL RESOLUTION OF INTERMEDIATES FOR THE SYNTHESIS OF DEXTROCETIRIZINE AND LEVOCETIRIZINE | UCB FARCHIM SA (CH) | 2006-09-14 | — | — | WO | claimed |
| US-6977301-B1 | Process for preparing (S) and (R)—2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide | UCB, S.A. (BE) | 2005-12-20 | — | — | US | claimed |
| US-20050182069-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | COSSEMENT ERIC (BE) | 2005-08-18 | — | — | US | claimed |
| US-20040122021-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl)-4-[(4-methylphenyl)sulfonyl) piperazine | COSSEMENT ERIC (BE) | 2004-06-24 | — | — | US | claimed |
| US-20040122023-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | COSSEMENT ERIC (BE) | 2004-06-24 | — | — | US | claimed |
| EP-0955295-B1 | Therapeutically active levorotatory and dextrorotatory 1-((4-chlorophenyl)phenylmethyl) piperazines | UCB SA (BE) | 2004-05-19 | — | — | EP | claimed |
| EP-1413307-A1 | Therapeutically active levorotatory and dextrorotatory 1-(4-chlorophenyl)phenylmethyl piperazines | UCB S.A. (BE) | 2004-04-28 | — | — | EP | claimed |
| US-20030204089-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | COSSEMENT ERIC (BE) | 2003-10-30 | — | — | US | claimed |
| US-20030092911-A1 | Hydrolysis in presence of phase transfer agents; antiallergens | EGIS GYOGYSZERGYAR RT. (HU) | 2003-05-15 | — | — | US | claimed |
| EP-1233954-A1 | A PROCESS FOR THE PREPARATION OF 2- 4-(ALPHA-PHENYL-P-CHLOROBENZYL)PIPERAZIN-1-YL]ETHOXY ACETIC ACID AND NOVEL INTERMEDIATES THEREFOR | EGIS GYOGYSZERGYAR RT. (HU) | 2002-08-28 | — | — | EP | claimed |
| WO-2001040211-A1 | A PROCESS FOR THE PREPARATION OF {2-[4-(α-PHENYL-p-CHLOROBENZYL)PIPERAZIN-1-YL]ETHOXY}ACETIC ACID AND NOVEL INTERMEDIATES THEREFOR | EGIS Gyógyszergyár Rt. (HU) | 2001-06-07 | — | — | WO | claimed |
| EP-0955295-A1 | Therapeutically active levorotatory and dextrorotatory 1-((4-chlorophenyl)phenylmethyl) piperazines | UCB, S.A. (BE) | 1999-11-10 | — | — | EP | claimed |
| EP-0617028-A1 | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulfonyl piperazine | U C B, S.A. (BE) | 1994-09-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122021-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl)-4-[(4-methylphenyl)sulfonyl) piperazine | RPLP1, QDPR, RPLP2 | HRH1 135/4885DRD3 482/4885USP2 2673/4885 |
| US-20030204089-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | RPLP1, QDPR, PRLHR | HRH1 135/4885DRD3 448/4885USP2 2584/4885 |
| US-20030092911-A1 | Hydrolysis in presence of phase transfer agents; antiallergens | CMA1, NAT1, CPN1 | HRH1 8/4885DRD3 2986/4885USP2 970/4885 |
| US-20050182069-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | QDPR, COMT, PRLHR | HRH1 236/4885DRD3 426/4885USP2 2505/4885 |
| US-20040122023-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | RPLP1, QDPR, PRLHR | HRH1 135/4885DRD3 448/4885USP2 2584/4885 |
| US-20080269489-A1 | Pyroglutamate Salts and Their Use in the Optical Resolution of Intermediates for the Synthesis of Dextrocetirizine and Levocetirizine | QPCT, QRFPR, GLUL | HRH1 563/4885DRD3 3124/4885USP2 1452/4885 |
| US-20060252934-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl]piperazine | QDPR, PRLHR, COMT | HRH1 251/4885DRD3 419/4885USP2 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.